Dataset from A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).

This is a randomized, open-label, multi-center, global, Phase III study to determine the
efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy
versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal
growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced
or metastatic NSCLC

本研究为一项随机、开放标签、多中心、全球性III期临床试验，旨在评估MEDI4736联合曲美木单抗（tremelimumab）疗法、MEDI4736单药疗法，对比铂类标准治疗（SoC）化疗，在表皮生长因子受体（EGFR）及间变性淋巴瘤激酶（ALK）野生型局部晚期或转移性非小细胞肺癌（NSCLC）患者一线治疗中的疗效与安全性。